Singapore markets closed
  • Straits Times Index

    3,102.21
    -32.66 (-1.04%)
     
  • S&P 500

    3,818.83
    -2.72 (-0.07%)
     
  • Dow

    31,029.31
    +82.32 (+0.27%)
     
  • Nasdaq

    11,177.89
    -3.65 (-0.03%)
     
  • BTC-USD

    19,083.39
    -1,000.09 (-4.98%)
     
  • CMC Crypto 200

    408.80
    -30.87 (-7.02%)
     
  • FTSE 100

    7,174.54
    -137.78 (-1.88%)
     
  • Gold

    1,813.10
    -4.40 (-0.24%)
     
  • Crude Oil

    109.76
    -0.02 (-0.02%)
     
  • 10-Yr Bond

    3.0930
    0.0000 (0.00%)
     
  • Nikkei

    26,393.04
    -411.56 (-1.54%)
     
  • Hang Seng

    21,859.79
    -137.10 (-0.62%)
     
  • FTSE Bursa Malaysia

    1,444.22
    -7.26 (-0.50%)
     
  • Jakarta Composite Index

    6,911.58
    -30.77 (-0.44%)
     
  • PSE Index

    6,155.43
    -147.76 (-2.34%)
     

Exicure Announces Presentation at 2022 H.C. Wainwright Global Life Sciences Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

CHICAGO, May 17, 2022--(BUSINESS WIRE)--Exicure, Inc. (NASDAQ: XCUR), an early-stage biotechnology company focused on the development of next generation nucleic acid therapies targeting RNA to address both genetic and non-genetic neurological disorders and hair loss disorders, today announced that CEO Matthias Schroff will provide a virtual presentation at the 2022 H.C. Wainwright Global Life Sciences Conference, occurring May 23-26, 2022.

The presentation will be available for on-demand viewing beginning May 24, 2022 at 7:00AM EST via the virtual conference link, and will be archived for 90 days.

Exicure will be taking 1x1 investor meetings with registered conference attendees.

About Exicure

Exicure, Inc. is an early-stage biotechnology company developing nucleic acid therapies targeting ribonucleic acid against validated targets to neurological disorders and hair loss. The team includes a diverse scientific group with expertise in nucleic acid chemistry, drug development and neuroscience. Headquartered in Chicago, Illinois, the Company conducts its discovery and development efforts in-house with a dedicated 30,000 square foot facility, including rapid and automated high throughput nucleic acid synthesis and screening. For further information, see www.exicuretx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220517005381/en/

Contacts

Karen Sharma
MacDougall
781-235-3060
ksharma@macdougall.bio

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting